We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

JN Medsys Introduces New Generation Digital PCR System

JN Medsys Introduces New Generation Digital PCR System content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
Targeting users that demand greater performance, the new system offers better specifications over the Clarity™ system, which is the first digital PCR product commercialised by the company. The new system, named Clarity™ Plus+, features improved consumables that provides at least 4 times more partitions than the Clarity™. It uses ultra-high density chips that can consistently generate more than 40,000 partitions per reaction, to provide greater dynamic range and better accuracy in digital PCR analysis.

The increase in partitions is designed around the same footprint, meaning that the new tube-strips still fit conventional thermal cyclers to allow up to 96 reactions per run as before. The new system also retains many features of Clarity™ which minimizes the risk of contamination, dead volume and significant sample loss that may be seen in other systems. The new system also comes with a more powerful Reader equipped with a 4- to 6-colour detection system to increase detection throughput in digital PCR.

With multiplexed detection of 4-6 targets per reaction and with up to 96 reactions per run, the system can now detect up to 384 or 576 different targets per run. The new system pushes the limits of digital PCR analysis by providing better dynamic range and accuracy, and possibly the highest detection throughput. “To tackle increasingly demanding applications such as in liquid biopsy, more powerful digital PCR systems capable of better performances are required.” says Dr Johnson Ng, founder and CEO of JN Medsys. “The increased partition number allow users to analyse samples over a wider dynamic range of concentrations. Rare mutations or low abundance targets can also be detected with greater sensitivity by reducing competition from different primer and probe sets in multiplex assays. In addition, the new system will have detection throughput comparable to most qPCR systems. We are truly excited by the possibilities provided by this new system.” Dr Ng added. The new system will be made available to early users in the second quarter of 2018.